Doxorubicin-Rosuvastatin-Trastuzumab combination

The combination of doxorubicin, rosuvastatin, and trastuzumab represents a therapeutic approach studied for treating HER2-positive breast cancer while attempting to mitigate cardiotoxicity. This combination consists of three distinct medications: Doxorubicin, an anthracycline chemotherapy agent that intercalates into DNA and inhibits topoisomerase II, preventing DNA replication; Trastuzumab (Herceptin), a humanized monoclonal antibody that targets the HER2 receptor, preventing its dimerization and inhibiting HER2-mediated malignant transformation; and Rosuvastatin, a statin medication that has shown protective effects against chemotherapy-induced cardiotoxicity. The combination addresses several therapeutic goals: - **Anti-cancer efficacy**: Both doxorubicin and trastuzumab have proven efficacy against HER2-positive breast cancer. Doxorubicin works by intercalating into DNA and inhibiting topoisomerase II, while trastuzumab binds to the extracellular segment of HER2 to prevent its dimerization. - **Cardioprotection**: The addition of rosuvastatin aims to reduce the cardiotoxicity associated with doxorubicin and trastuzumab. Studies have shown that rosuvastatin can attenuate cardiotoxicity by alleviating systemic inflammation and reducing cardiac biomarkers like high-sensitivity cardiac troponin I (hs-cTnI) and interleukin-6 (IL-6).